Cargando…

Patient-reported outcome measures in a pharmacokinetic study with sunitinib, a prospective cohort study

PURPOSE: During treatment with tyrosine kinase inhibitors, such as sunitinib, patients experience treatment and/or disease-related symptoms. Although application of patient-reported outcome measures (PROMs) enhances early recognition of symptoms, early clinical trials are focused on symptom severity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koldenhof, J. J., Lankheet, N. A. G., Steeghs, N., Teunissen, S. C. C. M., Witteveen, P. O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018583/ https://www.ncbi.nlm.nih.gov/pubmed/29464389 http://dx.doi.org/10.1007/s00520-018-4075-7

Ejemplares similares

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
por: Lankheet, N A G, et al.
Publicado: (2014)

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies
por: Hamberg, P, et al.
Publicado: (2010)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients
por: Numakura, Kazuyuki, et al.
Publicado: (2018)

Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
por: Kloth, Jacqueline S. L., et al.
Publicado: (2015)

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer
por: Diekstra, MH, et al.
Publicado: (2017)

Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab
por: Walraven, Maudy, et al.
Publicado: (2018)

A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer
por: Chow, L. Q. M., et al.
Publicado: (2011)

Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors
por: Wang, Erjian, et al.
Publicado: (2020)

Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors
por: Khosravan, Reza, et al.
Publicado: (2021)

Pharmacokinetics and bioequivalence of sunitinib and Sutent(®) in Chinese healthy subjects: an open-label, randomized, crossover study
por: Wang, Yanli, et al.
Publicado: (2023)

Prospective practice survey of management of cetuximab-related skin reactions
por: Lugtenberg, R. T., et al.
Publicado: (2020)

Patient-reported outcome measures after COVID-19: a prospective cohort study
por: Wong, Alyson W., et al.
Publicado: (2020)

Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study()
por: Chen, Yen-Yang, et al.
Publicado: (2014)

Sunitinib: Colitis: case report
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of Sunitinib
por: Noda, Satoshi, et al.
Publicado: (2012)

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
por: Wolter, P, et al.
Publicado: (2008)

Postoperative Adjuvant Sorafenib or Sunitinib for Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus: a Prospective Cohort Study
por: Gu, Liangyou, et al.
Publicado: (2017)

Understanding and optimizing fish counting techniques based on electrical impedance measurements
por: Nowak, Lukasz J., et al.
Publicado: (2023)

Case Report: Treatment of systemic mastocytosis with sunitinib
por: Molderings, Gerhard J., et al.
Publicado: (2017)

Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study
por: Tullemans, Bibian M. E., et al.
Publicado: (2022)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J J, et al.
Publicado: (2018)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J. J., et al.
Publicado: (2017)

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
por: Boven, E, et al.
Publicado: (2010)

Validation of the Dutch version of the Edmonton Symptom Assessment System
por: van der Baan, Frederieke H., et al.
Publicado: (2020)

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib
por: Mohammad, H., et al.
Publicado: (2021)

Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study
por: Heysell, Scott K, et al.
Publicado: (2022)

A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma
por: Lewin, J, et al.
Publicado: (2014)

Myelosuppression by sunitinib is flt-3 genotype dependent
por: van Erp, N P, et al.
Publicado: (2010)

Frailty and checkpoint inhibitor toxicity in older patients with melanoma
por: Bruijnen, Cheryl P., et al.
Publicado: (2022)

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
por: Khosravan, Reza, et al.
Publicado: (2016)

Validity of the Parsley Symptom Index—an Electronic Patient-Reported Outcomes Measure Designed for Telehealth: Prospective Cohort Study
por: Williams, Hants, et al.
Publicado: (2022)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Prospective multisite cohort study of patient‐reported outcomes in adults with new‐onset seizures
por: Foster, Emma, et al.
Publicado: (2021)

Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors
por: Wang, Erjian, et al.
Publicado: (2021)

Angiosarcoma of the Retroperitoneum: Report on a Patient Treated with Sunitinib
por: Yoo, Changhoon, et al.
Publicado: (2009)

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
por: Beuselinck, B, et al.
Publicado: (2013)

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
por: Gilabert, M, et al.
Publicado: (2013)

Systematic review and cost-effectiveness of pharmacokinetically guided sunitinib individualized treatment for patients with metastatic renal cell carcinoma
por: Chen, Tingting, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qpd0364p47u0464kv3004qs62e